Jennifer L. Sauter

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.5K citations · Full text

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi, Francisco Sánchez-Vega, Konnor La et al. · Journal of Clinical Oncology · 2018 · 1.4K citations · Full text

Immunology, Pathology, Immunotherapy +18

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi et al. · Cancer Cell · 2018 · 1.2K citations · Full text

Immunology, Pathology, Immune Cell Therapy +16

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

Ming‐Sound Tsao, Keith M. Kerr, Mark Kockx et al. · Journal of Thoracic Oncology · 2018 · 793 citations · Full text

Real-life Clinical Samples, Biomarker (Medicine), Translational Medicine +12

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Tricia R. Cottrell, Elizabeth D. Thompson, Patrick M. Forde et al. · Annals of Oncology · 2018 · 557 citations · Full text